Godavari Biorefineries Ltd. announced that the China National Intellectual Property Administration (CNIPA) has granted its patent for "5-HYDROXY-1,4-NAPHTHALENEDIONE FOR USE IN THE TREATMENT OF CANCER." This patent covers a novel class of compounds demonstrating strong inhibitory effects on cancer and cancer stem cells in in vitro studies, with significant efficacy against multiple cancer cell types, including breast and prostate cancer. The announcement was made on July 15, 2025, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Key Highlights
- Patent Grant: The China National Intellectual Property Administration (CNIPA) has granted Godavari Biorefineries a patent for a novel class of compounds.
- Compound Name: 5-HYDROXY-1,4-NAPHTHALENEDIONE.
- Therapeutic Use: Treatment of cancer.
- Efficacy: Demonstrated strong inhibitory effects on cancer and cancer stem cells in in vitro studies.
- Cancer Types: Significant efficacy against multiple cancer cell types, including breast and prostate cancer.
Strategic Implications
The granting of this patent in China marks a significant milestone for Godavari Biorefineries, strengthening its intellectual property portfolio and opening new avenues for cancer treatment research and development. The patented compounds have shown promising results in preclinical studies, indicating potential for future therapeutic applications.Company Information
- Company: Godavari Biorefineries Ltd
- Stock Exchange: National Stock Exchange of India Limited, BSE Limited
- Script Symbol: GODAVARIB
- Script Code: 544279
